Investigating how CES1 affects lung blood vessel health in pulmonary arterial hypertension
The Role of the CES1 in the Pathogenesis of Pulmonary Arterial Hypertension
This study is looking at how a protein called CES1 affects the health of tiny blood vessels in the lungs, which could help us find new ways to treat pulmonary arterial hypertension (PAH) and improve the lives of people living with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-11176379 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of carboxylesterase 1 (CES1) in the development of pulmonary arterial hypertension (PAH), a serious condition that leads to high blood pressure in the lungs and heart failure. The study examines how CES1 influences the health of pulmonary microvascular endothelial cells (PMVECs), which are crucial for forming blood vessels. By exploring the metabolic processes and signaling pathways involved, the research aims to identify potential new therapeutic targets for improving patient outcomes. Patients with PAH may benefit from insights gained about CES1's role in their condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with pulmonary arterial hypertension, particularly those experiencing severe symptoms or unresponsive to current therapies.
Not a fit: Patients with pulmonary arterial hypertension who have already responded well to existing treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that improve blood vessel function and reduce the severity of pulmonary arterial hypertension.
How similar studies have performed: Previous research has shown promising results in understanding metabolic pathways in PAH, suggesting that exploring CES1 could yield valuable insights.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: De Jesus Perez, Vinicio a — Stanford University
- Study coordinator: De Jesus Perez, Vinicio a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.